|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: P3H1 |
Gene summary for P3H1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | P3H1 | Gene ID | 64175 |
| Gene name | prolyl 3-hydroxylase 1 | |
| Gene Alias | GROS1 | |
| Cytomap | 1p34.2 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q32P28 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64175 | P3H1 | LZE2T | Human | Esophagus | ESCC | 8.57e-06 | 4.89e-01 | 0.082 |
| 64175 | P3H1 | LZE4T | Human | Esophagus | ESCC | 1.95e-03 | 1.37e-01 | 0.0811 |
| 64175 | P3H1 | LZE24T | Human | Esophagus | ESCC | 7.75e-08 | 2.14e-01 | 0.0596 |
| 64175 | P3H1 | P2T-E | Human | Esophagus | ESCC | 1.75e-28 | 3.98e-01 | 0.1177 |
| 64175 | P3H1 | P4T-E | Human | Esophagus | ESCC | 9.46e-18 | 4.66e-01 | 0.1323 |
| 64175 | P3H1 | P5T-E | Human | Esophagus | ESCC | 5.77e-05 | 1.78e-01 | 0.1327 |
| 64175 | P3H1 | P8T-E | Human | Esophagus | ESCC | 3.10e-15 | 3.05e-01 | 0.0889 |
| 64175 | P3H1 | P9T-E | Human | Esophagus | ESCC | 4.48e-09 | 2.58e-01 | 0.1131 |
| 64175 | P3H1 | P10T-E | Human | Esophagus | ESCC | 2.70e-51 | 8.02e-01 | 0.116 |
| 64175 | P3H1 | P11T-E | Human | Esophagus | ESCC | 5.88e-10 | 4.52e-01 | 0.1426 |
| 64175 | P3H1 | P12T-E | Human | Esophagus | ESCC | 7.69e-18 | 3.67e-01 | 0.1122 |
| 64175 | P3H1 | P15T-E | Human | Esophagus | ESCC | 5.22e-12 | 3.50e-01 | 0.1149 |
| 64175 | P3H1 | P16T-E | Human | Esophagus | ESCC | 4.87e-23 | 4.10e-01 | 0.1153 |
| 64175 | P3H1 | P17T-E | Human | Esophagus | ESCC | 2.93e-06 | 3.33e-01 | 0.1278 |
| 64175 | P3H1 | P19T-E | Human | Esophagus | ESCC | 3.45e-14 | 6.72e-01 | 0.1662 |
| 64175 | P3H1 | P20T-E | Human | Esophagus | ESCC | 7.79e-13 | 2.65e-01 | 0.1124 |
| 64175 | P3H1 | P21T-E | Human | Esophagus | ESCC | 1.17e-26 | 5.68e-01 | 0.1617 |
| 64175 | P3H1 | P22T-E | Human | Esophagus | ESCC | 9.89e-15 | 3.71e-01 | 0.1236 |
| 64175 | P3H1 | P23T-E | Human | Esophagus | ESCC | 1.53e-17 | 3.18e-01 | 0.108 |
| 64175 | P3H1 | P24T-E | Human | Esophagus | ESCC | 1.81e-07 | 2.44e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
| GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
| GO:0061077110 | Esophagus | ESCC | chaperone-mediated protein folding | 56/8552 | 67/18723 | 1.52e-10 | 4.36e-09 | 56 |
| GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:00181263 | Esophagus | ESCC | protein hydroxylation | 23/8552 | 27/18723 | 2.60e-05 | 2.19e-04 | 23 |
| GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
| GO:00195114 | Esophagus | ESCC | peptidyl-proline hydroxylation | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
| GO:00603485 | Esophagus | ESCC | bone development | 115/8552 | 205/18723 | 1.67e-03 | 7.72e-03 | 115 |
| GO:00329631 | Esophagus | ESCC | collagen metabolic process | 62/8552 | 104/18723 | 2.90e-03 | 1.22e-02 | 62 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:00109764 | Esophagus | ESCC | positive regulation of neuron projection development | 91/8552 | 163/18723 | 5.72e-03 | 2.13e-02 | 91 |
| GO:005070810 | Esophagus | ESCC | regulation of protein secretion | 142/8552 | 268/18723 | 9.31e-03 | 3.24e-02 | 142 |
| GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:005082122 | Liver | HCC | protein stabilization | 139/7958 | 191/18723 | 1.61e-17 | 1.71e-15 | 139 |
| GO:006107712 | Liver | HCC | chaperone-mediated protein folding | 56/7958 | 67/18723 | 4.86e-12 | 2.14e-10 | 56 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| P3H1 | SNV | Missense_Mutation | rs368488426 | c.2069N>C | p.Arg690Pro | p.R690P | Q32P28 | protein_coding | deleterious_low_confidence(0.02) | unknown(0) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
| P3H1 | SNV | Missense_Mutation | rs746983037 | c.1363G>A | p.Glu455Lys | p.E455K | Q32P28 | protein_coding | deleterious(0.03) | benign(0.02) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| P3H1 | SNV | Missense_Mutation | novel | c.1734N>T | p.Glu578Asp | p.E578D | Q32P28 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-AR-A5QP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| P3H1 | SNV | Missense_Mutation | c.1918N>A | p.Glu640Lys | p.E640K | Q32P28 | protein_coding | tolerated(0.07) | probably_damaging(0.917) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| P3H1 | SNV | Missense_Mutation | c.1313N>G | p.Glu438Gly | p.E438G | Q32P28 | protein_coding | deleterious(0.04) | probably_damaging(0.91) | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| P3H1 | SNV | Missense_Mutation | rs201236270 | c.1625N>T | p.Thr542Met | p.T542M | Q32P28 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| P3H1 | SNV | Missense_Mutation | novel | c.1406N>T | p.Ser469Phe | p.S469F | Q32P28 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-PE-A5DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | CR | |
| P3H1 | insertion | Frame_Shift_Ins | novel | c.1272_1273insTTCTGCAAGCTGCTGGGAAGGCCTACTGATTGTGGCTCTGC | p.Met425PhefsTer15 | p.M425Ffs*15 | Q32P28 | protein_coding | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| P3H1 | insertion | Frame_Shift_Ins | novel | c.501_502insTGTTGCTTGTC | p.Thr168CysfsTer20 | p.T168Cfs*20 | Q32P28 | protein_coding | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| P3H1 | insertion | In_Frame_Ins | novel | c.499_500insCTCAGAGGT | p.His167delinsProGlnArgTyr | p.H167delinsPQRY | Q32P28 | protein_coding | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |